Overview

Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer

Status:
Recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

The performance of SGM-101, an intraoperative imaging agent, will be compared to that of standard "white light" visualization during surgical resections of colorectal cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Surgimab

Treatments:

Antibodies, Monoclonal